Health
Question mark over effectiveness of Pfizer-BioNTech COVID-19 vaccine in obese people – BioPharma-Reporter.com
New data may have serious implications for the development of vaccination strategies for COVID-19, particularly in individuals with obesity.
A study by a team of researchers based at Istituti Fisioterapici Ospitalieri (IFO) in Rome, Italy, aimed to analyse the antibody response following two doses of the Pfizer/BioNTech COVID-19 vaccine, BNT162B2, in 248 healthcare workers. They also looked to evaluate how the antibody titer in those participants changed in relation to age, gender and body mass index (BMI).
Of the cohort studied, 158 were women (63.7%) and 90 were men (36.3%). The average age was 47 years, with the range going from 23…
-
General13 hours agoMontana’s house was gutted by an accidental fire. Then her landlord accused her of starting it
-
Noosa News15 hours agoUniversity of Queensland researchers survey population of endangered White’s Seahorse
-
Business13 hours agoThe smartest ASX dividend stocks to buy with $5,000 right now
-
Business12 hours ago2 must-have ASX shares to buy for dividend income investors